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Abstract
Responsiveness to cytokine-mediated acute inflammatory stimuli of the highly differentiated and polarized WIF-B hybrid
cell line was studied by measuring the induction of K1-acid glycoprotein and K2-macroglobulin mRNAs after interleukin-1,
interleukin-6 and tumor necrosis factor-K treatments in the presence of dexamethasone. Compared with their Fao parent,
WIF-B cells were 10 times more responsive to 24-h interleukin-6 induction regarding K2-macroglobulin induction. At
variance from the response measured in Fao cells, the late effects of interleukin-6 treatment confirmed the higher sensitivity
of WIF-B cells to this cytokine as a 72-h treatment was 10 times more effective than a 24-h treatment at inducting K1-acid
glycoprotein mRNA. These findings highlight the hepatocyte differentiation of WIF-B cells compared with other hepatoma
cell lines, with respect to the regulation of acute-phase protein gene expression. They also make WIF-B cells a convenient
model to study the molecular effects of interleukin-6 in terms of transduction and/or transcription, and the many cross-talks
that occur during the regulation of acute-phase protein gene expression. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Among the various models proposed for studying
hepatocyte functions in vitro, no cells exhibit both
stable hepatocyte di¡erentiation and functional cell
polarity. Even the most di¡erentiated rat hepatoma
cell lines do not express all of the hepatocyte func-
tions and are known to be unpolarized [1,2]. Freshly
isolated hepatocytes, cultured for a few days on plas-
tic or collagen, rapidly lose gene expression and se-
cretory capability [3]. When cultured on extracellular
matrices such as Matrigel, they exhibit a better func-
tional stability of hepatocyte-speci¢c gene expression
[4,5]. Even, in these conditions, the recovery of hep-
atocyte polarity is only partial and transient [6].
WIF-B hybrid cells which originate from Fao rat
hepatoma and WI-38 human ¢broblasts represent
an alternative to other models for studying hepato-
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cyte structure and function in vitro [7^9]. Relative to
their Fao parent, WIF-B cells re-express many di¡er-
entiated functions of hepatocytes as: (1) they develop
structurally individualized and functional bile canal-
iculi ; and (2) they produce large amounts of serum
albumin [9]. In most of the previously studied hep-
atoma cell lines, the inductive e¡ects of cytokines on
acute-phase plasma protein mRNA expression are
not superimposable with those observed in hepato-
cytes. In rat hepatocytes, the responses to interleu-
kin-1 L (IL-1) and interleukin-6 (IL-6) are almost
identical [10,11]. Conversely, the sensitivity of hepa-
toma cells to IL-6 is markedly inhibited, compared
with the e¡ects of IL-1 [12^18]. In this work, we
addressed the following question: does the re-expres-
sion of di¡erentiated hepatocyte functions in WIF-B
cells include the recovery of an equilibrated induc-
tion pro¢le between these two cytokines? We tested
the e¡ects of IL-1, IL-6 and tumor necrosis factor-K
(TNF-K) on K1-acid glycoprotein (AGP) and K2-
macroglobulin (K2-M) mRNA contents. The expres-
sion of these two glycoproteins dramatically increase
during acute in£ammatory processes and is known to
be induced by cytokines in the presence of glucocor-
ticoids in rat hepatocytes [10,11] and hepatoma cells
[19^21,15,16]. Whereas AGP gene expression is in-
duced by both IL-1 and IL-6, K2-M induction is ex-
clusively IL-6-dependent [22]. We show that, unlike
their parental Fao cell line, WIF-B cells are strongly
responsive to IL-6-mediated induction of AGP and
K2-M. The high responsiveness of WIF-B cells to IL-
6 is consistent with a high degree of hepatocyte dif-
ferentiation relative to other hepatoma cell lines, and
makes them a good model for studying molecular
mechanisms of IL-6-mediated transduction and tran-
scription.
2. Materials and methods
2.1. Cell culture and treatments
WIF-B cells were cultured in F12 Coon’s-modi¢ed
medium (Sigma, St. Louis, MO) supplemented with
5% FCS (Dutcher, Rungis, France) and HAT (1035
M hypoxanthine, 4U1037 M aminopterine and
1.5U1035 M thymidine) (Polylabo, Strasbourg,
France). The working density was reached 8^10
days after plating at a density of 7000 cells/cm2.
Fao cells were cultured in the same medium without
HAT. They were plated at the density of 10 000 cells/
cm2 and reached the working density after 3 days.
Cells were treated in triplicate wells with 1036 M
dexamethasone and/or recombinant human IL-1, IL-
6 or TNF-K (Immugenex, Los Angeles, CA) at con-
centrations ranging from 0.05 to 500 ng/ml. Some
inductions were repeated daily for 3 days. At the
end of the induction period, cells were lysed by 5 M
guanidine thiocyanate, 0.1 M EDTA, pH 7.4 and
subjected to mRNA quanti¢cation. The speci¢city
of each cytokine was tested by inhibiting mRNA
induction with cytokine-speci¢c antibodies (data not
shown).
2.2. mRNA quanti¢cation
Quantitative molecular hybridization with cRNA
probes and RNase protection assay were performed
directly on unfractionated cells solubilized in guani-
dine thiocyanate according to Kaabache et al. [23].
Brie£y, cell lysates (10 Wl) were subjected to cohy-
bridization with either AGP or K2-M and GAPDH
labeled riboprobe (2 Wl, 105 cpm). Rat AGP cDNA
[24], K2-M [25] and GAPDH [26] cDNA inserts were
subcloned into pBluescript II SK phagemid vectors.
Riboprobe synthesis was performed in the presence
of [K-32P]UTP (50 WCi, 400 Ci/mM) and T3 (AGP)
or T7 (K2-M and GAPDH) RNA polymerase. Quan-
titative analysis was performed from gels exposed to
Instant Imager (Packard, Meriden, CT) to overcome
signal saturation observed on autoradiographic ¢lms
(X-OMAT ¢lms, Eastman Kodak, Rochester, NY).
Signal ratios between protected fragments (AGP/
GAPDH and K2-M/GAPDH) were calculated for
each sample and relative changes were determined
by comparing these ratios to the mean ratio meas-
ured in dexamethasone-treated cells.
3. Results
Dexamethasone is known to be a strong inducer of
AGP in vivo and in vitro on rat hepatocytes
[10,12,27,28]. Moreover, glucocorticoids are indis-
pensable for cytokines to induce in vitro AGP and
K2-M expression [10,12,19]. The same feature was
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previously observed with Fao rat hepatoma cells :
1036 M dexamethasone concentrations is needed
for full stimulation, but dexamethasone alone is not
e¡ective in increasing the expression of acute-phase
proteins [15,16]. WIF-B and Fao cells cultured with-
out dexamethasone did not produce detectable
amounts of AGP (6 0.5 ng/106 cells/24 h). However,
in the presence of 1036 M dexamethasone, AGP se-
cretion reached 31 þ 3 and 18 þ 6 ng/106 cells/24 h for
WIF-B and Fao, respectively (not shown). At the
mRNA level, AGP was hardly detectable without
dexamethasone treatment. When cells were treated
with 1036 M dexamethasone, AGP mRNA content
increased and was approximately twice higher in
WIF-B than in Fao cells (Fig. 1). Thus, owing to
the increased sensitivity of mRNA detection using
the RNase protection assay, it appears that dexa-
methasone was able to induce AGP gene expression
in both cell lines. Cells were treated by 1036 M dexa-
methasone in all subsequent experiments.
According to Andus et al. [16], we tested a unique
concentration of 50 ng/ml of each of the cytokines.
This concentration was e¡ective at inducing AGP
mRNA in Fao cells. Both Fao and WIF-B cells
were treated for 24 h with each cytokine, then
AGP and K2-M mRNA were quanti¢ed (Fig. 2).
As expected from the literature [15,16,18], AGP
mRNA was moderately induced by IL-6 and TNF-
K in Fao cells, whereas a marked e¡ect was observed
after IL-1 treatment (Fig. 2a). Compared with hep-
atocytes in which AGP mRNA is almost equally
induced by IL-6 and IL-1 [10,11], WIF-B cells, as
well as many other hepatoma cell lines are poorly
responsive to 24-h IL-6-mediated AGP mRNA in-
duction [12^18]. To test if such a poor response re-
sults from a malfunction in the regulation of AGP
gene expression or might involve a defective IL-6
responsiveness, we also compared the induction of
Fig. 1. E¡ect of dexamethasone on the mRNA levels of AGP
and K2-M in Fao and WIF-B cells. Cells were treated for 3 days
with 1036 M dexamethasone. After removal of the culture
medium and lysis in guanidine thiocyanate, cell lysates were co-
hybridized with the cRNA probes of GAPDH and either AGP
or K2-M. Double-strand RNase-protected fragments were ana-
lyzed by acrylamide gel electrophoresis and autoradiography.
Fig. 2. E¡ect of IL-1, IL-6 and TNF on the cellular mRNA
contents of AGP (a) and K2-M (b) in Fao and WIF-B cell
lines. In the presence of 1036 M dexamethasone, cells were
treated for 24 h with 50 ng/ml of recombinant human IL-6, IL-
1 or TNF. GAPDH, AGP and K2-M cellular mRNA cellular
contents were measured by RNase protection assay. The signal
ratios of AGP to GAPDH and K2-M to GAPDH signals were
compared with those measured in dexamethasone-treated cells
and expressed as induction factors. In each panel, the autora-
diography from one representative experiment is shown. In the
bar charts, each bar is the mean induction factor þ S.E.M. of
three to ¢ve independent experiments.
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K2-M mRNA after IL-6 treatment in the two cell
lines (Fig. 2b). As K2-M mRNA was induced approx-
imately 5 times more in WIF-B than in Fao, we
conclude that IL-6 responsiveness was not altered
in this cell line and was even higher than observed
in Fao cells. To quantify more precisely the improve-
ment of the response to IL-6 induction in WIF-B
versus Fao cells, we analyzed the dose^response
curves of IL-6-mediated AGP and K2-M induction
(Fig. 3). As suggested by the data shown in Fig.
2a, AGP induction was approximately identical in
the two cell lines, but at IL-6 concentrations higher
than 50 ng/ml, WIF-B cells appeared to be more
sensitive to IL-6 than Fao cells (Fig. 3, top). Regard-
ing K2-M induction (Fig. 3, bottom), we found that
WIF-B cells were approximately 10 times more sen-
sitive to IL-6 than Fao cells as the dose^response
curve was shifted to the left by 1 decade. These
data suggest that WIF-B cells, which appear to be
intrinsically more sensitive to IL-6 than Fao cells in
terms of K2-M mRNA induction, do not exhibit full
AGP induction by IL-6. As suggested by the dose^
response curves which did not reach a steady-state,
the maximum response to IL-6 was not reached, even
at very high IL-6 concentrations (500 ng/ml). To test
whether it was possible to revert part of the inhibi-
tion of IL-6-mediated AGP induction, we decided
not to increase cytokine concentrations to avoid
toxic e¡ects, but to increase the duration of the treat-
ment with IL-6. The experiments we performed con-
Fig. 3. E¡ect of increasing concentrations of IL-6 on AGP and
K2-M mRNA contents after 24 h of treatment of Fao and
WIF-B cells in the presence of dexamethasone. After mRNA
assay, the ratios of AGP to GAPDH and K2-M to GAPDH
signals were calculated for each experimental point and ex-
pressed as induction factors relative to the ratio measured in
control cells.
Fig. 4. Time-dependent e¡ect of IL-6 on AGP and K2-M
mRNA contents. In the presence of 1036 M dexamethasone,
WIF-B and Fao cells were treated for 24, 48 or 72-h with 50
ng/ml IL-6, then cells were lysed and AGP and K2-M mRNA
contents were measured by RNase protection assay. GAPDH
mRNA was cohybridized to normalize AGP and K2-M meas-
urement. The results are expressed as mean induction factor þ
S.E.M. of three independent experiments relative to dexametha-
sone-treated control cells.
Fig. 5. Dose-dependent e¡ect of IL-6 on AGP mRNA contents
measured after a 24- and 72-h treatment in WIF-B cells. After
mRNA assay, the ratios of AGP to GAPDH signals were cal-
culated for each experimental point and expressed as induction
factors relative to the ratio measured in control cells.
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sisted of 24-, 48- and 72-h inductions with 50 ng/ml
IL-6 in both cell lines. AGP and K2-M mRNAs were
quanti¢ed in each case. As shown in Fig. 4, it ap-
pears that K2-M induction was maintained for at
least 72 h in both cell lines. More strikingly, in the
case of AGP, a 72-h treatment was approximately
6 times more e¡ective than observed after 1 or 2
days of induction, whereas the response of Fao cells
did not change during the same period. The compar-
ison of the dose^response curves performed after 24
or 72 h of treatment indicate that after 72 h of treat-
ment, AGP induction was approximately 10 times
more e¡ective than after a 24-h treatment (Fig. 5).
4. Discussion
WIF-B cells are already known to secrete large
amounts of murine albumin [9] making them a highly
di¡erentiated in vitro model of hepatic cells. How-
ever, many other secretory capabilities of WIF-B
cells have not yet been explored, in particular with
respect to acute-phase protein induction. In this
work, the main criterion used to analyze the re-
sponses of WIF-B and Fao cells to cytokine-medi-
ated in£ammatory stimuli was the induction pattern
measured with each of the AGP and K2-M mRNAs.
All cell treatments were performed in the presence of
1036 M dexamethasone since, as previously stated by
Andus et al. [16], in Fao hepatoma cells, glucocorti-
coids are essential to reach maximal e¡ects with the
3 cytokines tested. In both cell lines, the responses to
cytokines were dramatically enhanced by glucocorti-
coids as IL-1 and TNF-K alone only slightly in-
creased AGP mRNA content and induction was
not observed with IL-6 alone (data not shown).
Moreover, dexamethasone treatment was indispensa-
ble to maintain a stable baseline of AGP mRNA
levels.
With respect to the induction of K2-M mRNA
contents which strictly depends on the e¡ects of IL-
6, we showed that WIF-B cells are 10 times more
responsive than measured in Fao cells. These data
indicate ¢rst that the IL-6-mediated transduction
pathway involved in K2-M induction is functional
in WIF-B cells. The greater sensitivity of WIF-B cells
to IL-6 compared with Fao might involve either an
increased IL-6 receptor expression at the cell surface,
or an improvement in signal transduction mediated
via the JAK/STAT3 pathway [29,30]. The ¢rst hy-
pothesis could be at least in part eliminated as IL-
6-receptor mRNA quanti¢cation did not show di¡er-
ences between the two cell lines (data not shown).
However, we could not rule out the possibility that
the polarized phenotype of WIF-B cells [8] might
allow a better cell surface expression of the IL-6
receptor. Whatever the molecular mechanism under-
lying the increased response of WIF-B to IL-6, this
feature indicates that WIF-B cells exhibit increased
di¡erentiated phenotype relative to other hepatoma
cells, as judged by comparison with the inducibility
of K2-M mRNA in hepatocytes [10,20].
With respect to AGP mRNA induction, the situa-
tion is more complicated. In hepatocytes, AGP
mRNA expression may be increased by many in-
ducers. Besides glucocorticoids, these inducers in-
clude cytokines which use either the IL-1-mediated
transduction pathway via C/EBPL and C/EBPN acti-
vation [31,32], or the IL-6-mediated pathway. The
latter involves two fast transduction pathways:
JAK/STAT3 [29,30,33] and C/EBP L post-transla-
tional activation [34] and the slower induction of
C/EBPN at the transcriptional level [29,30,34]. After
3 days of treatment, part of AGP inducibility was
restored thus re-equilibrating the e¡ects of IL-6 and
IL-1 by comparison with other hepatoma cells. This
phenomenon might be evocative of the late activa-
tion of the C/EBPN pathway already shown in hep-
atocytes [34]. Given that K2-M induction did not in-
volve C/EBP activation [33,35], this hypothesis is
consistent with the di¡erent IL-6 responsiveness we
observed between K2-M and AGP. Another argu-
ment in favor of the long-lasting activation of the
C/EBPN pathway is the fact that the inductive e¡ect
of IL-1 on AGP mRNA contents was identical after
24- and 72-h treatments (data not shown). AGP ex-
pression is strongly repressed in hepatoma cells. For
instance, Fao cells contain 0.5% of the amount of
AGP mRNA found in hepatocytes (B. Lardeux, un-
published data). Although a similar repression was
also observed in WIF-B cells, the late inductive ef-
fects of IL-6 on AGP mRNA we observed also ar-
gues in favor of a higher hepatocyte di¡erentiation of
this cell line in terms of regulation of the acute-phase
response. In conclusion, WIF-B cells constitute a
very interesting cell model to study IL-6 transduc-
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tion, long-term cytokine-mediated e¡ects on the tran-
scription of AGP gene and to analyze the cross-talks
that occur during the regulation of acute-phase pro-
tein gene expression in hepatic cells.
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